Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
LeMajor I know you are absolutely correct with the MMs game of "keep it moving". somewhat like a cat with a mouse taking a bite over a prolonged period, but we have no movement, no volume, no activity, no interest.... is PH deliberately not prodding this mouse as part of a Baldrick cunning plan...it is starting to feel very much like a Blackadder sketch. I am sure it is coming the results are what we need.
Whatever SRRA Oncology are doing its looking positive, could resist a quick look. HC Wainwright raising their buy/target price to 51 dollar.....currently 26.62 dollar.....that's some bullish flag waving....we need a big flag!
If I am honest I don't entirely understand the 11 number form 4 ..... pre-agreed deposits and acquires .... seemed at a glance more pre agreed acquires (buys) than deposits, either way such activity being positive. Those NASDAQ share forums are plenty of RA RA Big storyboards, make us look reserved,all tea and cucumber sandwiches :)
With 3 out of 5 programmed clinical R&D including the use of 737 there has to be a bullish win for SAR in there, including our association with SRRA....you average investor with no knowledge must still be missing this investment link with SAR.
3rd RNS Out.....Correction we were right the first time, we did actually mean 2022 not 2026
This board has got more than Stacey's Mom going on today, its all happening....wish we had same volume of trades as we do have volume of posts....great reading......., talk about satire (the use of humor, irony, exaggeration, or ridicule to expose and criticize people's stupidity or vices, particularly in the context of contemporary politics and other topical issues surrounding SAR......its like been in the film Don't Look Up....nothing would surprise me today.
Best use of word today goes to "Sanctimonious" and it was well chosen for an apt post, but "megablunders" arguably not a word was amusingly hardcore.
“Don't Look Up” in the film is a campaign, essentially telling Americans (and others) to pretend that the comet even when visible in the sky doesn't exist (here's looking at you, climate change deniers and anti-vaxxers). SAR is surely going to make a bigger impact +/-? than that comet on my finances.
Added to that waiting for a priority report on a Birthday Cake, the need to remake Snow-white without little people, the real % increase on NI and that friendly bunch camping in the Ukraine
TF its Friday :)
WTF One minute we are driving consolidation next action is dilution.........as for date that is reprehensibly atrociousness...not sure what to make of what is occurring...........an RNS should have the governance process of 4 or five eyes over it before it leaves the building.
A 54-year-old accountant leaves a letter for his wife one evening which read: "Dear Wife, I am 54 years old, and by the time you get this letter I will be at the Grand Hotel with my beautiful and sexy eighteen year old secretary."
When he arrived at the hotel, there was a letter waiting for him that read as follows: "Dear Husband, I too am 54 years old, and by the time you receive this letter I will be at the Savoy Hotel with my eighteen year old toy boy. Because you are an accountant, you will surely appreciate that 18 goes into 54 many more times than 54 goes into 18.
Its not a bad shout, the Sierra LTH of shares will understand the value 737 presents to them and SAR and the volume of new investors could equally have an interest in investing in SAR.......... "we seem to be a Best Kept Secret" If Spank Sierra is peaking then look to our 4.10 its a strong buy.
Thanks Heckler et all..........Sierra Oncology in their words "Topline Pivotal Data Announcement" of their current Pipeline of ongoing clinical studies as indicated on the clinical program on their website, very clearly shows in black and white the use of 737 as a combination in 3 of its 5 product development studies ...... 2 also being in cooperative trials. Looks incredibly positive for SAR.
As far as the investment market goes, I think its like having an original Picasso in the loft that no one knows about.
Sierra success well deserved... If the investment market can see the connection of 737 to SAR (our Picasso) , that in my mind would velcro us into a parallel upward sp trajectory....will though, this be as obvious to the investors who clearly are not as well read as many on this board.....that absence of knowledge and research about 737's connection with SAR could as others suggest mean that we don't see the immediate rush to buy SAR......that possibly being delayed until there is some more obvious announcements or revenue on its way. Its great news all round, and hats off to Sierra......by association I have even more positive vibes about having this in my investment portfolio.
Just sat and watched the Edison Open House, had Tim been a greyhound he would have caught the rabbit out of the trap, but whilst fast it was informative and it reaffirmed the direction for me. That direction being a consistent strategy with a consistent message..... gave me plenty of confidence that our expectations are build on solid research & development. GLA over next period.
With these questions on the agenda it looks a great open house platform for health sector investors ... Edison Questions for Tim Mitchell...looking forward to this today....
Tell us about your business model and strategy for commercialisation.
Why is there so much interest in JAK inhibitors?
What is your strategy to progress SDC-1801 through clinical development after the first clinical trials in mid-2022? Are you actively assessing licensing/partnership opportunities?
Are you planning to explore the recent positive data on SDC-1801’s immune- modulation properties in COVID-19?
Might other respiratory diseases benefit from this?
How has the CHK1 programme that was out-licensed to Sierra Oncology progressed and how do you see it developing in the near to medium term?
What is your cash runway? Where will the recent funding be directed and are you looking for more investment?
Which milestones should investors focus on in the coming year?
Spank, I get it, from my seat IMO there' s nothing to make me nervous at all, and no reason for this not to turnaround, in fact SP should be getting knocked out of the park with the endless potential........ we are in an abyss or a lull waiting for R&D results and some positive communication on the same. ...will be hanging on every word tomorrow.
Sharing eveyones frustration, just logged in to look at trading volume and there isn't enough trade to blow SP one way or another, although I didn't think in Jan we would be sub 4p. Hopefully some volume following the 25th Jan. Currently sat well below value.... what a day to buy.
I don't see how you can factor in your loss to date as in principle on paper the loss that you personally have incurred pre or post consolidation is the same (I am in a similar situation)
What I do get and consider relevant to me also is that the loss you've incurred of 3.25 pence per share seems a lot more likely a recoverable rise that would happen with lesser resistance than the more challenging multiple of pound notes to get back your £3.25 loss per share.
My nervousness on the consolidation was more that the reduced volume would then allow more shares to be created to raise additional ongoing funding and the dilution that would follow.... which for consolidation to get my vote I would want to see part of a shareholders agreement some assurances that this won't occur.
It would be interesting to see what incoming intel you gleam on JPM.
I still have hopes of GSK in one form or other coming in to the equation and if so I am looking forward to posting the problem of what will I do with my investment windfall :)
Enjoy the day.
SHeck...You are of course correct. The aggregate value of a holders shares would be exactly as you describe. This being currently equating to £4.30 at 100/1 .
In theory that's exactly the case although in practice the detail of the consolidation announcement is likely to cause a further drop so I personally would like to see a more representativly robust or true SP as our starting point for the consolidation. I also think that the in theory statement isn't always as the investor sees a consolidation play out as in practice some value "can" not "will" trickle out....that's just my view.
On a positive note I think that mmediately after consolidation, with some media attention, I wouldn't be surprised if we saw some large pendulum swings and increased trading break outs, with traders making a buck on SAR over a short period before it settles down again. That's what I am hoping and find exciting about what is occurring.
January (imminently???) should see some massive news on this....we should shortly have some enlightenment on our Chinese Partner, who they are? and how this licensee will progress? to full commercialisation that being so it is made available to the public for use in China and most importantly generating a sales revenue and milestone payments.
At the AGM their lips were sealed but alongwith pantomine season in Dec you could tell that SAR's goose was smugly sitting on a golden egg.
Tim had previously commented : "We are delighted with this important global licensing deal for our FLT3+Aurora inhibitor programme, which could generate significant milestone revenue in the next nine months. We believe the Licensee has the resources and expertise to further advance these molecules through the clinic to commercialisation, in China.”
Good evening Sog....Fully concur, funding with no debt gives us choices so not reliant or subservient to a must have offering sale to a large pharma... which puts us in a very strong position for negotiation(s).
This however doesn't lessen my concern on future release of new shares to raise these funds post any consolidation... time will tell, but the added comfort of a share holder agreement, on future limited release of new shares and long time line for any such release would make me more comfortable.
Some good informative posts this evening, thanks
My absence of concern re the consolidation goes out of the window if the increased SP created by reducing the current volume of shares finds that more shares are then to be released to raise more funds. That type of dilution really would be a kick in the nether regions for the current share holders.
Possibility of this happening is sadly high, a common trait of any broker cycle of continually raising funds.
So is the main reasons for SAR share consolidation to either tidy up the company’s share capital or reduce the number of shares, thus the underlying share price increases in an effort to make them more attractive to investors. We can't rule out that they will be well positioned to release new shares to investors.
Again as an investor hopefully, post consolidation, I (we) will have the same interest in the company albeit with a lower number of shares with a higher nominal value. So if we are able to influence or have a say in the next steps by PH/SAR I would like to see, if feasible, a shareholder agreement in place limiting when and how many new shares could be released... either none or a sensible number over a very long timeline to avoid my concerns of dilution.
One hopes however, if the science comes good with some or just one groundbreakingly priceless offering we will be two busy counting the pounds rather than the pennies in the SP.